Gastrointestinal stromal tumors: actin expression, a new prognostic factor?

Area of Science:

• Oncology
• Gastroenterology
• Surgical Pathology

Background:

• Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract.
• Accurate prognostic factors are crucial for tailoring treatment and predicting patient outcomes.
• Previous studies have identified various factors, but further investigation into new prognostic indicators is warranted.

Purpose of the Study:

• To analyze the clinical outcomes of patients with GISTs.
• To identify novel prognostic factors influencing survival and disease-free survival in GIST patients.
• To evaluate the diagnostic challenges of gastric GISTs that may mimic epithelial neoplasms.

Main Methods:

• A retrospective analysis of 35 patients diagnosed with GIST and surgically treated between 2000 and 2008.
• Data collected included patient demographics, tumor location, clinical presentation, and pathological findings (including actin expression).
• Statistical analysis was performed to identify factors associated with survival and disease-free survival.

Main Results:

• The 1- and 5-year survival rates were 94.3% and 88.6%, respectively. The 1- and 2-year disease-free survival rates were 91.4% and 88.6%, respectively.
• Lower disease-free survival was linked to constitutional syndrome, small bowel GIST, and actin-negative tumors.
• Poorer overall survival was associated with male gender, abdominal mass, constitutional syndrome, and retroperitoneal GIST location.

Conclusions:

• Masculine gender, constitutional syndrome, abdominal mass, small bowel and retroperitoneal locations, and actin-negative tumors are identified as adverse prognostic factors for GIST.
• Gastric GISTs can present diagnostic challenges, potentially being mistaken for epithelial neoplasms, which may influence surgical management.
• These findings contribute to a better understanding of GIST prognosis and may aid in clinical decision-making.